Genmab Announces Pricing Of Private Offering Of Senior Secured Notes And Senior Unsecured Notes

Genmab has priced $1.5 billion of 6.25% senior secured notes due 2032 and $1.0 billion of 7.25% senior unsecured notes due 2033 at par, with closing expected December 3, 2025, and completed syndication of a $2.0 billion senior secured term loan B that supplements a previously syndicated $1.0 billion term loan A and $500 million revolving credit facility. The company said net proceeds from the notes, borrowings under the new credit facilities and cash on hand will be used to fund the consideration and fees for its pending acquisition of Merus N.V. This financing package materially increases Genmab’s near- and medium-term debt load and establishes the funding structure for the transaction, with implications for leverage and credit metrics as the acquisition closes.

Analysis

Genmab has priced $1.5 billion of 6.250% senior secured notes due 2032 and $1.0 billion of 7.250% senior unsecured notes due 2033 at par (100.000%), with the offering expected to close on December 3, 2025. The company also completed syndication of a $2.0 billion senior secured term loan B that supplements an earlier $1.0 billion senior secured term loan A and a $500 million secured revolving credit facility; Genmab states net proceeds, borrowings under the new facilities and cash will fund the consideration and fees for the pending acquisition of Merus N.V.

The financing package materially increases secured and unsecured debt on Genmab’s balance sheet across staggered maturities (2032–2033) and fixes interest expense at elevated coupons relative to typical investment-grade issuance, implying heavier near- and medium-term interest burden and higher leverage post-close. Pricing at par and completion of the syndicated term loan B reduce execution risk for closing, while the presence of both secured and unsecured paper concentrates downside risk for equity if credit metrics deteriorate.

Market-impact signals are muted (market impact score 0.3, mixed sentiment), suggesting limited immediate market reaction, but investors should expect rating agencies and lenders to re-assess leverage and covenant headroom once the acquisition closes and pro forma financials are released. Key risks to monitor are pro forma leverage and covenant terms, integration outcomes for Merus, and the company’s ability to service higher fixed interest costs without eroding liquidity.

Key Decisions for Investors

• Model pro forma leverage and interest expense incorporating the $1.5bn 6.25% secured notes, $1.0bn 7.25% unsecured notes and the $3.0bn of term loans to assess potential downgrade or covenant breach risk
• Monitor close on December 3, 2025 and confirm use of proceeds and covenant language before increasing exposure; consider waiting for pro forma guidance before adding to equity positions
• If holding equity, consider partial hedges to credit exposure (protective puts or CDS where available) or reduce position size given the material increase in fixed-rate debt and higher interest burden
• If considering credit or bond allocations, differentiate between secured and unsecured tranches: secured notes/term loans have priority but still increase systemic leverage risk, while unsecured paper carries higher coupon-driven default sensitivity